CSPC Pharmaceutical Group (HK:1093) has released an update.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
CSPC Pharmaceutical Group has entered into an exclusive license agreement with BeiGene for the global development, manufacture, and commercialization of its innovative cancer drug, SYH2039. The deal includes upfront payments of $150 million, with potential milestone payments of up to $1.685 billion, plus royalties. SYH2039, a promising drug targeting MTAP-deficient tumors, has shown strong preclinical results and is currently in Phase I clinical trials in China.
For further insights into HK:1093 stock, check out TipRanks’ Stock Analysis page.
